{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T12:45:21Z","timestamp":1774788321762,"version":"3.50.1"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/bor.0b013e32835fd5e5","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T14:10:05Z","timestamp":1362492605000},"page":"304-309","source":"Crossref","is-referenced-by-count":26,"title":["New developments in gout"],"prefix":"10.1097","volume":"25","author":[{"given":"Leslie","family":"Harrold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R2-5-20210128","first-page":"2403","article-title":"Epidemiology of gout: is the incidence rising J R","volume":"29","author":"Arromdee","year":"2002","journal-title":"heumatol"},{"key":"R3-5-20210128","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1046\/j.1523-1755.2003.t01-2-00171.x","article-title":"The association between gout and nephrolithiasis in men: the Health Professionals Follow-Up Study.","volume":"64","author":"Kramer","year":"2003","journal-title":"Kidney Int"},{"key":"R4-5-20210128","first-page":"1582","article-title":"Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population.","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"R5-5-20210128","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0149-2918(03)80158-3","article-title":"A literature review of the epidemiology and treatment of acute gout.","volume":"25","author":"Kim","year":"2003","journal-title":"Clin Therap"},{"key":"R6-5-20210128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2474-12-103","article-title":"Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population.","volume":"12","author":"Primatesta","year":"2011","journal-title":"BMC Musculoskeletal Disord"},{"key":"R7-5-20210128","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.amjmed.2006.02.044","article-title":"Updates in the management of gout.","volume":"120","author":"Keith","year":"2007","journal-title":"Am J Med"},{"key":"R8-5-20210128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.amjmed.2011.11.010","article-title":"Nature versus nurture in gout: a twin study.","volume":"125","author":"Krishnan","year":"2012","journal-title":"Am J Med"},{"key":"R9-5-20210128","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R11-5-20210128","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford, England)"},{"key":"R12-5-20210128","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R13-5-20210128","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"R14-5-20210128","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R15-5-20210128","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R16-5-20210128","first-page":"577","article-title":"Treatment of chronic gout.","volume":"28","author":"Li-Yu","year":"2001","journal-title":"Can we determine when urate stores are depleted enough to prevent attacks of gout J Rheumatol"},{"key":"R17-5-20210128","first-page":"1324","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout Arthritis R","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"heum"},{"key":"R18-5-20210128","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.4049\/jimmunol.174.8.5016","article-title":"TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation.","volume":"174","author":"Liu-Bryan","year":"2005","journal-title":"J Immunol"},{"key":"R19-5-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome.","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"R20-5-20210128","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/ni.1631","article-title":"Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization.","volume":"9","author":"Hornung","year":"2008","journal-title":"Nat Immunol"},{"key":"R21-5-20210128","first-page":"39","article-title":"The role of the NLRP3 inflammasome in gout.","volume":"4","author":"Kingsbury","year":"2011","journal-title":"J Inflamm Res"},{"key":"R22-5-20210128","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout.","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"R24-5-20210128","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/acr.21690","article-title":"Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.","volume":"64","author":"Schumacher","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R25-5-20210128","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"S10","key":"R26-5-20210128","first-page":"S144","article-title":"Long-term safety of canakinumab in patients with gout arthritis.","volume":"64","author":"So","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R27-5-20210128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"R28-5-20210128","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3899\/jrheum.111375","article-title":"Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.","volume":"39","author":"Strand","year":"2012","journal-title":"J Rheumatol"},{"issue":"S10","key":"R29-5-20210128","first-page":"S159","article-title":"Clinical efficacy outcomes with up to 3 years of pegloticase treatment for refractory chronic gout.","volume":"64","author":"Becker","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R31-5-20210128","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2165\/11592290-000000000-00000","article-title":"Difficult-to-treat gouty arthritis: a disease warranting better management.","volume":"71","author":"Schlesinger","year":"2011","journal-title":"Drugs"},{"issue":"S10","key":"R32-5-20210128","first-page":"S1021","article-title":"Efficacy and safety of Lesinurad (RDEA594), A novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: preliminary results the randomized, double-blind, placebo-controlled, phase 2B extension study.","volume":"63","author":"Sundy","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"S10","key":"R33-5-20210128","first-page":"S1632","article-title":"Arhalofenate is a novel dual-acting agent with uricosuric and anti-inflammatory properties.","volume":"64","author":"Choi","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"S10","key":"R34-5-20210128","first-page":"S150","article-title":"Ulodesine (BCS4208) long-term safety when added to allopurinol in the chronic management of gout: a Phase 2 24-week blinded safety extension and vaccine challenge study.","volume":"64","author":"Hollister","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R36-5-20210128","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.amjmed.2006.01.020","article-title":"Alcohol consumption as a trigger of recurrent gout attacks.","volume":"119","author":"Zhang","year":"2006","journal-title":"Am J Med"},{"key":"R37-5-20210128","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/annrheumdis-2011-201215","article-title":"Purine-rich foods intake and recurrent gout attacks.","volume":"71","author":"Zhang","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R38-5-20210128","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men.","volume":"350","author":"Choi","year":"2004","journal-title":"N Engl J Med"},{"key":"R39-5-20210128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.20761","article-title":"Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey.","volume":"52","author":"Choi","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R40-5-20210128","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study.","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"key":"R41-5-20210128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e328335ef38","article-title":"A prescription for lifestyle change in patients with hyperuricemia and gout.","volume":"22","author":"Choi","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"R42-5-20210128","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1002\/art.34677","article-title":"Cherry consumption and decreased risk of recurrent gout attacks.","volume":"64","author":"Zhang","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R43-5-20210128","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1093\/rheumatology\/keq256","article-title":"The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial.","volume":"49","author":"Zhu","year":"2010","journal-title":"Rheumatology (Oxford, England)"},{"key":"R44-5-20210128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1742395310378761","article-title":"Patients and providers view gout differently: a qualitative study.","volume":"6","author":"Harrold","year":"2010","journal-title":"Chronic Illn"},{"key":"R45-5-20210128","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2474-13-180","article-title":"Patients knowledge and beliefs concerning gout and its treatment: a population based study.","volume":"13","author":"Harrold","year":"2012","journal-title":"BMC Musculoskeletal Disord"},{"key":"R46-5-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s100670050005","article-title":"How is gout managed in primary care A review of current practice and proposed guidelines.","volume":"19","author":"Pal","year":"2000","journal-title":"Clin Rheumatol"},{"key":"R47-5-20210128","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","article-title":"Patient and provider barriers to effective management of gout in general practice: a qualitative study.","volume":"71","author":"Spencer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R48-5-20210128","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/ar2659","article-title":"Adherence with urate-lowering therapies for the treatment of gout.","volume":"11","author":"Harrold","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R49-5-20210128","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/ard.2007.076182","article-title":"Uric acid lowering therapy: prescribing patterns in a large cohort of older adults.","volume":"67","author":"Solomon","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R50-5-20210128","first-page":"1575","article-title":"Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.","volume":"31","author":"Riedel","year":"2004","journal-title":"J Rheumatol"},{"key":"R51-5-20210128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semarthrit.2008.01.011","article-title":"Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature.","volume":"38","author":"Harrold","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"R52-5-20210128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective.","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R53-5-20210128","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","article-title":"Comparison of drug adherence rates among patients with seven different medical conditions.","volume":"28","author":"Briesacher","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"S10","key":"R54-5-20210128","first-page":"S817","article-title":"Feasibility of using a pharmacist-based gout management clinic to improve serum uric acid in gout patients in a large prepaid health plan.","volume":"64","author":"Goldfien","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R56-5-20210128","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R57-5-20210128","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e32835fd5e5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:05:17Z","timestamp":1620947117000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201305000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e32835fd5e5","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}